S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:ORGO

Organogenesis Stock Forecast, Price & News

$9.82
+0.28 (+2.94%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.36
$10.01
50-Day Range
$9.54
$15.46
52-Week Range
$4.56
$24.34
Volume
366,509 shs
Average Volume
1.05 million shs
Market Capitalization
$1.26 billion
P/E Ratio
21.35
Dividend Yield
N/A
Beta
1.72
30 days | 90 days | 365 days | Advanced Chart
Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.


Organogenesis logo

About Organogenesis

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Headlines

Organogenesis (NASDAQ:ORGO) Shares Gap Down to $10.47
November 29, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
910
Year Founded
N/A

Sales & Book Value

Annual Sales
$338.30 million
Cash Flow
$0.24 per share
Book Value
$1.47 per share

Profitability

Net Income
$17.95 million
Pretax Margin
14.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
55,060,000
Market Cap
$1.26 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

2.67 out of 5 stars

Medical Sector

36th out of 1,390 stocks

Pharmaceutical Preparations Industry

10th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

Is Organogenesis a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Organogenesis stock.
View analyst ratings for Organogenesis
or view top-rated stocks.

How has Organogenesis' stock price been impacted by COVID-19 (Coronavirus)?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORGO shares have increased by 229.5% and is now trading at $9.82.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Organogenesis?

Organogenesis saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 9,150,000 shares, an increase of 17.0% from the October 14th total of 7,820,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 8.3 days. Currently, 14.6% of the shares of the stock are sold short.
View Organogenesis' Short Interest
.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Organogenesis
.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) issued its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $113.75 million for the quarter, compared to the consensus estimate of $112.10 million. Organogenesis had a net margin of 13.82% and a trailing twelve-month return on equity of 36.76%. During the same quarter in the prior year, the firm posted $0.19 earnings per share.
View Organogenesis' earnings history
.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $458 million-$470 million, compared to the consensus revenue estimate of $462.50 million.

What price target have analysts set for ORGO?

3 equities research analysts have issued 12-month target prices for Organogenesis' stock. Their forecasts range from $20.00 to $27.00. On average, they anticipate Organogenesis' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 144.4% from the stock's current price.
View analysts' price targets for Organogenesis
or view top-rated stocks among Wall Street analysts.

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Gary S. Gillheeney, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Patrick R. Bilbo, Chief Operating Officer
  • David Charles Francisco, Chief Financial Officer
  • Lori H. Freedman, Vice President & General Counsel
  • Brian Grow, Chief Commercial Officer

What other stocks do shareholders of Organogenesis own?

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.28%), Deerfield Management Company L.P. Series C (5.80%), Granahan Investment Management Inc. MA (1.65%), Morgan Stanley (1.11%), Macquarie Group Ltd. (0.96%) and Assenagon Asset Management S.A. (0.88%). Company insiders that own Organogenesis stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Avista Capital Managing Member, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Glenn H Nussdorf, Michael W Katz, Michael W Katz, Starr Wisdom and Wayne D Mackie.
View institutional ownership trends for Organogenesis
.

Which major investors are selling Organogenesis stock?

ORGO stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Millennium Management LLC, Morgan Stanley, Goldman Sachs Group Inc., Renaissance Technologies LLC, Hamilton Lane Advisors LLC, Cubist Systematic Strategies LLC, and Citigroup Inc.. Company insiders that have sold Organogenesis company stock in the last year include Albert Erani, Dennis Erani, Gary S Gillheeney, Glenn H Nussdorf, and Starr Wisdom.
View insider buying and selling activity for Organogenesis
or view top insider-selling stocks.

Which major investors are buying Organogenesis stock?

ORGO stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., BlackRock Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, CastleArk Alternatives LLC, Pura Vida Investments LLC, Jabodon PT Co., and Deerfield Management Company L.P. Series C. Company insiders that have bought Organogenesis stock in the last two years include 2016 Organo 10-Year Grat U/ Gn, Avista Capital Managing Member, Michael W Katz, and Wayne D Mackie.
View insider buying and selling activity for Organogenesis
or or view top insider-buying stocks.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $9.82.

How much money does Organogenesis make?

Organogenesis has a market capitalization of $1.26 billion and generates $338.30 million in revenue each year. The company earns $17.95 million in net income (profit) each year or $0.46 on an earnings per share basis.

How many employees does Organogenesis have?

Organogenesis employs 910 workers across the globe.

What is Organogenesis' official website?

The official website for Organogenesis is organogenesis.com.

Where are Organogenesis' headquarters?

Organogenesis is headquartered at 85 Dan Road, Canton MA, 02021.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at (781) 575-0775 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.